Study and Treatment of Inflammatory Muscle Diseases

  • STATUS
    Recruiting
  • participants needed
    4000
  • sponsor
    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Updated on 12 September 2021
electrocardiogram
local anesthetic
urine tests
pulmonary function test
x-rays
MRI
weakness
white blood cells
apheresis
autoimmune disease
muscle biopsy
rheumatic diseases
dermatomyositis
polymyositis
muscle wasting
myopathy
biopsy incision

Summary

This study of inflammatory muscle diseases-polymyositis and dermatomyositis and related disorders-will examine what causes these diseases and describe the clinical features (signs and symptoms) associated with them. Inflammation and degeneration of skeletal muscles in these disorders leads to weakness and muscle wasting. The skin, lungs and other organs may also be involved.

Patients 16 years of age and older with polymyositis, dermatomyositis, or a related disorder may be eligible for this study. Participants will undergo a complete history and physical examination, including routine blood and urine tests. Additional procedures for diagnosis, treatment or research may include:

  1. Blood sample for genetic studies.
  2. Muscle biopsy-removal of a tissue sample for microscopic examination. Under local anesthetic, a 1/2- to 1-inch long incision is made in the thigh or upper arm, and a small piece of muscle is removed.
  3. Electromyography-measurement of the electrical activity of a muscle. A needle is inserted through the skin into a muscle to record its electrical activity.
  4. Magnetic resonance imaging-visualization of organs or tissues, using a magnetic field and radio waves. The patient lies on a table inside a narrow cylinder (the MRI scanner) with a strong magnetic field for the scanning.
  5. Manual muscle strength testing by a physiotherapist.
  6. Swallowing studies using ultrasound (imaging using sound waves) and X-rays (barium swallow) to evaluate swallowing and speaking abilities.
  7. Questionnaires on swallowing ability and ability to perform daily living activities
  8. Pulmonary function tests-measurement of movement of air in and out of the lungs. The patient breathes into a machine to evaluate lung function.
  9. Chest X-rays to evaluate lung function.
  10. Electrocardiogram and, if necessary, Holter monitoring (measurement of the electrical activity of the heart) and echocardiogram (ultrasound imaging of the heart) to evaluate heart function.
  11. Apheresis-collection of white blood cells for research. Whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through the same needle or through a second one placed in the other arm.
  12. MR guided muscle biopsy-measurement of glycogen in muscle tissue using magnetic resonance imaging. Certain patients may undergo this experimental procedure to compare MRI findings with those of muscle biopsy. The affected muscles are identified using MRI and the biopsy incision is made. MRI is then used to guide the biopsy needle to the muscle and a small piece is removed.

Patients who are eligible for experimental treatment studies will be offered the opportunity to join them. Others will be advised of treatment recommendations.

Description

Polymyositis, dermatomyositis and related disorders, also known as the idiopathic inflammatory myopathies (IIM), are an uncommon, heterogeneous group of diseases. This is an omnibus protocol designed to continue our description of this rare group of diseases, further delineate important groups of patients, and obtain useful material for further study of immunological abnormalities, pathogenesis and etiology of IIM. Often the diagnosis of an IIM can be confused with other illness (such as adult-onset dystrophies), and therefore, we will be evaluating patients with other illnesses (who are referred with a preliminary diagnosis of an IIM) (1). Patients evaluated with IIM will receive (with informed consent) the best standard therapies available and consideration for entry into any therapeutic protocols. MRI will be performed on healthy volunteers to help develop a mathematical method for quantitating edema of muscle MRI in patients (2). MRI/PET will be performed on some patients and on healthy volunteers to evaluate its role in understanding muscle disease.

Details
Condition Dermatomyositis, Autoimmune disease, CONNECTIVE TISSUE DISEASE, Myositis, Dermatosis, Polymyositis, INCLUSION BODY MYOSITIS, Dermatomyositis (Connective Tissue Disease), Congenital Skin Diseases, Polymyositis (Inflammatory Muscle Disease), Skin Conditions, Connective Tissue Diseases, Idiopathic Inflammatory Myopathies
Clinical Study IdentifierNCT00001265
SponsorNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

All eligible patients are invited to participate in this protocol. Patients
are adults and minors, aged 16 or higher, with possible idiopathic muscle
disease (suspected or confirmed). Since both men and women are affected with
the disease, both sexes will be studied. All ethnic and racial groups are at
risk and will be included. Pregnant women and women who intend to become
pregnant during the study will be eligible since this disease affects both
segments of the population. This protocol proposes responsible inclusion of
pregnant women and the justification for this derives in part from the fact
that women (who are suffering from autoimmune and rheumatic diseases) lack
data from which to make informed decisions about health care during pregnancy
INCLUSION OF PREGNANT WOMEN
The majority of patients with autoimmune disease are women and of these
individuals, the majority are of childbearing age. Furthermore, pregnancy is a
risk factor for fluctuations in autoimmune disease activity, including organ-
and life- threatening flares. The majority of our study population is
comprised of women. The exclusion of women who become pregnant from systemic
study by way of our natural history protocol, threatens both the well-being of
the individual women (owing to the standard of care provision of the protocol)
and the systematic discovery of pregnancy-specific data concerning the
immunopathological basis of autoimmune disease. Skewed understanding from a
restricted natural history study may leave vulnerable groups open to
disproportionate harm owing to inequities in research. In other words
automatic disqualification due to pregnancy denies women agency in the issue
of gender equity for access to research and in addition the systematic
exclusion of pregnant women prevents generalizability of information to help
under-resourced and marginalized populations, nationwide
In summary
The cost of exclusion of pregnant women with myositis 1) insufficient evidence concerning how to manage such disease for the population, and 2) lack of access to the best myositis specific advice for individuals enrolled in the protocol who are unlikely to have access to specialty care outside of the NIH
The cost of exclusion in research with regard to fetal safety derives from the fact that preeclampsia, eclampsia, preterm birth and miscarriage are higher in women who do not have access to subspecialty care. In this situation, reticence on the part of nonspecialists to treat active autoimmune disease during pregnancy or lack of access to appropriate treatment may lead to harm to women and their fetuses
The pregnant body possesses a unique hormonal and immunological environment. Similarly, it metabolizes medications in a manner different from non-pregnant women, let alone men. Hence, there is no reasonable path towards generating important biomedical knowledge other than to include pregnant women in this protocol
The tension between protection by exclusion and the presumption of inclusion
in research protocols has been specifically addressed by the US Institute of
Medicine (now National Academy of Medicine) and the Task Force on Research
Specific to Pregnant Women and Lactating Women to advise the Secretary of
Health and Human Services regarding gaps in knowledge and research on safe and
effective therapies for pregnant and lactating women, and both have both
weighed in as favoring the presumption of inclusion
(<https://www.nichd.nih.gov/about/advisory/PRGLAC>). Our study falls in line
with these position papers since it is responsible (it benefits, patients and
their fetuses and provides relevant data to the population at large) and
because it is low risk (it is standard of care, only, and does not invoke
experimental interventions)
Healthy volunteers will be eligible only if they are adults aged 18 or older
and only if they are willing to provide informed consent. There is no benefit
to the healthy volunteers; however their inclusion will provide invaluable
information in comparison to the patients for the purpose of research
Participation of NIH Staff or family members of study team members
NIH staff and family members of study team members may be enrolled in this
study as this population meets the study entry criteria. Neither participation
nor refusal to participate as a subject in the research will have an effect
either beneficial or adverse, on the participant s employment or position at
NIH
Every effort will be made to protect participant information, but such
information may be available in medical records and may be available to
authorized users outside of the study team in both an identifiable an
unidentifiable manner
The NIH Information Sheet on NIH Staff Research Participation will be made
available. Please see section for consent of NIH Staff

Exclusion Criteria

Children (age less than 16 years) are excluded
Subjects with severe active infection (such as requiring intravenous antibiotics) or other co-morbidities that in the opinion of the investigator would warrant exclusion
Subjects or their legal guardians who are unable or unwilling to give informed consent/assent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note